The FDA said that Biogen has provided substantial evidence that its new Alzheimers drug is effective. While the drug (“aducanumab”) has not been formally approved by the FDA, the statement sent shares in the Cambridge-based biotech firm up 44% yesterday.
The New Paper
This story is from the November 5, 2020 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.
